IFPMA Marks World TB Day
Ahead of March 24's World TB Day, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) has confirmed the biopharma industry's commitment to the World Health Organization (WHO) drive to eradicate tuberculosis and its campaign, “Wanted: Leaders for a TB-free world”, focusing on building commitment at all levels of the community. An IFPMA press releases notes that the biopharmaceutical industry is contributing to the TB challenge with R&D measures to improve access to treatments and to find more effective, safer, all-oral regimens to treat all forms of TB, and new vaccines for adolescents and adults. There are now over 60 R&D projects for TB medicines and vaccines in the pipeline, including seven products in phase III clinical trials. Recent breakthroughs made by Johnson & Johnson and Otsuka (bedaquiline and delamanid) for the treatment of MDR-TB are illustrative of new approaches being taken by biopharma companies to make broadening sustainable and responsible access a priority. "2018 is a critical year for the global TB community", writes IFPMA, "culminating with the first ever UN High-Level Meeting on TB on September 26, 2018".
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Real-World Data Demonstrates Efficacy of Apretude and Cabenuva in HIV Prevention, Treatment
March 14th 2025New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and treatment, with Apretude showing zero HIV acquisitions and Cabenuva maintaining high viral suppression rates.
